A novel three-dimensional stromal-based model for in vitro chemotherapy sensitivity testing of leukemia cells

Leukemia and Lymphoma

Volumn 55, Issue 2, 2014, Pages 378-391

  Aljitawi, Omar S ^a   Li, Dandan ^a   Xiao, Yinghua ^a   Zhang, Da ^b   Ramachandran, Karthik ^a   Stehno Bittel, Lisa ^a   Van Veldhuizen, Peter ^b   Lin, Tara L ^a   Kambhampati, Suman ^b   Garimella, Rama ^a,b  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Chemotherapy sensitivity; In vitro; Leukemia; Three dimensional

Indexed keywords

CYTARABINE; DOXORUBICIN; NERVE CELL ADHESION MOLECULE;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER MODEL; CELL CULTURE; CELL SUSPENSION; COCULTURE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG SCREENING; DRUG SENSITIVITY; FLOW CYTOMETRY; FLUORESCENCE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LEUKEMIA CELL; MESENCHYMAL STEM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT DURATION; TUMOR MICROENVIRONMENT;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE MARROW CELLS; CADHERINS; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; COCULTURE TECHNIQUES; CYTARABINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FLOW CYTOMETRY; HL-60 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LEUKEMIA; MESENCHYMAL STROMAL CELLS; MODELS, BIOLOGICAL;

EID: 84900010999     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.793323     Document Type: Article

References (32)

1. Kunz-Schughart L.A., Freyer JP, Hofstaedter F, et al The use of 3-D cultures for high-throughput screening: the multicellular spheroid model. J Biomol Screen 2004;9:273-285.
2. Cukierman E, Pankov R, Stevens D.R., et al Taking cell-matrix adhesions to the third dimension. Science 2001;294:1708-1712. (Pubitemid 33104840)
3. Lukashev ME, Werb Z. ECM signalling: orchestrating cell behaviour and misbehaviour. Trends Cell Biol 1998;8:437-441. (Pubitemid 28529716)
4. Delmer A, Marie IP, Thevenin D, et al Treatment of relapsing and refractory adult acute myeloid leukemia according to in vitro clono-genic leukemic cell drug sensitivity. Leuk Lymphoma 1993;10:67-71. (Pubitemid 23239860)
5. Khoury HJ, Garcia-Manero G, Borthakur G., et al A phase 1 dose-escalation study of ARRY-520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias. Cancer 2012;118: 3556-3564.
6. Wacheck V, Lahn M, Dickinson G., et al Dose study of the multi-kinase inhibitor, LY2457546, in patients with relapsed acute myeloid leukemia to assess safety, pharmacokinetics, and pharmacodynamics. Cancer Manag Res 2011;3:157-175.
7. Lapusan S, Vidriales MB, Thomas X, et al Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia. Invest New Drugs 2012;30:1121-1131.
8. Colmone A, Amorim M, Pontier A.L., et al Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells. Science 2008;322:1861-1865.
9. Li ZW, Dalton WS Tumor microenvironment and drug resistance in hematologic malignancies. Blood Rev 2006;20:333-342. (Pubitemid 44691998)
10. Lin SI, Kuo ML Cytotoxic function of umbilical cord blood natural killer cells: relevance to adoptive immunotherapy. Pediatr Hematol Oncol 2011;28:640-646.
11. Sipkins DA, Wei X, Wu T.W., et al In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment. Nature 2005;435:969-973. (Pubitemid 40896324)
12. Oran B, Wagner IE, DeFor T.E., et al Effect of conditioning regimen intensity on acute myeloid leukemia outcomes after umbilical cord blood transplantation. Biol Blood Marrow Transplant 2011;17: 1327-1334.
13. Burger IA, Peled A. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia 2009; 23:43-52.
14. McQueen T, Konopleva M, Andreeff M. Activity of targeted molecular therapeutics against primary AML cells: putative role of the bone marrow microenvironment. Blood 2005;106(Suppl. 1): Abstract 2304.
15. Kojima K, McQueen T, Chen Y., et al p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-l{alpha}-mediated down-regulation of CXCL12. Blood 2011;118:4431-4439.
16. Fischbach C, Chen R, Matsumoto T., et al Engineering tumors with 3D scaffolds. Nat Methods 2007;4:855-860. (Pubitemid 350055585)
17. Dainiak MB, Savina IN, Musolino I, et al Biomimetic macro-porous hydrogel scaffolds in a high-throughput screening format for cell-based assays. Biotechnol Prog 2008;24:1373-1383.
18. Blanco TM, Mantalaris A, Bismarck A., et al The development of a three-dimensional scaffold for ex vivo biomimicry of human acute myeloid leukaemia. Biomaterials 2010;31:2243-2251.
19. Colado E, Alvarez-Fernandez S, Maiso P., et al The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34 + immature phenotype. Haematologica 2008;93:57-66. (Pubitemid 351156152)
20. Nirmalanandhan VS, Duren A, Hendricks P., et al Activity of anticancer agents in a three-dimensional cell culture model. Assay Drug Dev Technol 2010;8:581-590.
21. Drexler HG, Quentmeier H, MacLeod R.A., et al Leukemia cell lines: in vitro models for the study of acute promyelocytic leukemia. Leuk Res 1995;19:681-691.
22. Asou H, Tashiro S, Hamamoto K., et al Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation. Blood 1991;77:2031-2036.
23. Zheng R, Bailey E, Nguyen B., et al Further activation of FLT3 mutants by FLT3 ligand. Oncogene 2011;30:4004-4014.
24. Burke PI, Diggs CH, Owens AH Ir. Factors in human serum affecting the proliferation of normal and leukemic cells. Cancer Res 1973;33:800-806.
25. Karp IE, Burke PI Influence of humoral regulators on proliferation and maturation of normal and leukemic cells. Cancer Res 1976;36: 1674-1679.
26. Hozumi M. Established leukemia cell lines: their role in the understanding and control of leukemia proliferation. Crit Rev Oncol Hematol 1985;3:235-277. (Pubitemid 15020982)
27. Zhi L, Wang M, Rao Q., et al Enrichment of N-cadherin and Tie2-bearing CD34+/CD38-/CD123 + leukemic stem cells by chemotherapy-resistance. Cancer Lett 2010;296:65-73.
28. Zhang I, Niu C, Ye L., et al Identification of the haematopoietic stem cell niche and control of the niche size. Nature 2003;425: 836-841. (Pubitemid 37351467)
29. Haug IS, He XC, Grindley I.C., et al N-cadherin expression level distinguishes reserved versus primed states of hematopoietic stem cells. Cell Stem Cell 2008;2:367-379. (Pubitemid 351455240)
30. Hosokawa K, Arai F, Yoshihara H., et al Cadherin-based adhesion is a potential target for niche manipulation to protect hematopoietic stem cells in adult bone marrow. Cell Stem Cell 2010;6:194-198.
31. Sacchetti B, Funari A, Michienzi S., et al Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell 2007;131:324-336. (Pubitemid 47592917)
32. Vaiselbuh SR, Edelman M, Lipton I.M., et al Ectopic human mesenchymal stem cell-coated scaffolds in NOD/SCID mice: an in vivo model of the leukemia niche. Tissue Eng Part C Methods 2010;16: 1523-1531.